Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The aim of the study was to assess risedronate's effect on bone mineral density in postmenopausal women with rheumatoid arthritis receiving glucocorticoids. We carried out a two center, 2 year, double-masked, placebo-controlled trial with a third year of nontreatment follow-up. We studied 120 women requiring long-term glucocorticoid therapy at > 2.5 mg/day prednisolone randomized to treatment with daily placebo; daily 2.5 mg risedronate; or cyclical 15 mg risedronate (2 out of 12 weeks). At 97 weeks, bone mineral density was maintained at the lumbar spine (+1.4%) and trochanter (+0.4%) in the daily 2.5 mg risedronate group, while significant bone loss occurred in the placebo group (-1.6%, p = 0.03; and 4.0%, p < 0.005, respectively). At the femoral neck, there was a nonsignificant bone loss in the daily 2.5 mg risedronate group (-1.0%) while in the placebo group bone mass decreased significantly (-3.6%, p < 0.001). The difference between placebo and daily 2.5 mg risedronate groups was significant at the lumbar spine (p = 0.009) and trochanter (p = 0.02) but did not reach statistical significance at the femoral neck. Although not significantly different from placebo at the lumbar spine, the overall effect of the cyclical regimen was similar to that of the daily 2.5 mg risedronate regimen. Treatment withdrawal led to bone loss in the risedronate groups that was significant at the lumbar spine. A similar number of patients experienced adverse events (including upper gastrointestinal events) across treatment groups and risedronate was generally well tolerated. Thus risedronate preserves bone mass in postmenopausal women with rheumatoid arthritis receiving glucocorticoids while patients receiving a placebo have significant bone loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Risedronate is also approved for treatment to increase bone mass in men with osteoporosis and for the prevention and treatment of osteoporosis in men and women who are either initiating or taking glucocorticoids [75].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [75]
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615 · cited 1×
“As inhibitors of bone resorption, bisphosphonates are becoming widely used in the management of postmenopausal osteoporosis [ 10 ].”
BackgroundSelf-citationPrevalence and incidence of vertebral deformities
Melton, L. J., Lane, A. W., Cooper, C., Eastell, R., O'Fallon, W. M., & Riggs, B. L. (1993) · Osteoporosis International · doi:10.1007/bf01623271 · Cited by 517
Self-citationPeel, N. F., Moore, D. J., Barrington, N. A., Bax, D. E., & Eastell, R. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.10.801 · Cited by 379
Self-citationA UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update
Eastell, R., Reid, D. M., Compston, J., Cooper, C., Fogelman, I., Francis, R. M., Hosking, D. J., Purdie, D. W., Ralston, S. H., Reeve, J., et al. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00408.x · Cited by 315 · cited 2×
“After low bone mass has developed, the use of other agents such as bisphosphonates has been recommended [ 4 ].”
BackgroundSelf-citationHAHN, T. J., HALSTEAD, L. R., & BARAN, D. T. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-1-111 · Cited by 308
Dykman, T. R., Gluck, O. S., Murphy, W. A., Hahn, T. J., & Hahn, B. H. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280402 · Cited by 281
Glucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Risk of vertebral fracture in women with rheumatoid arthritis.
Spector, T. D., Hall, G. M., McCloskey, E. V., & Kanis, J. A. (1993) · BMJ · doi:10.1136/bmj.306.6877.558 · Cited by 230
Cited by
Items 101–139 of 139
Cómo se puede prevenir y tratar la osteoporosis inducida por glucocorticoides
Danés, I., & Bosch, M. (2003) · Medicina Clínica · doi:10.1016/s0025-7753(03)73741-5 · Cited by 4
Rheumatic diseases, glucocorticoid treatment and bone mass: Recent developments
Mazzantini, M., & Lane, N. E. (2000) · Clinical and Experimental Rheumatology · Cited by 3
Chapurlat, R. D., & Delmas, P. D. (2001) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2001.tb11033.x · Cited by 3
Management of glucocorticoid-induced osteoporosis in rheumatic diseases
Shrestha, P., Popuri, S. B., Hoffer, C., Qureshi, A., Barzilay, J. I., Dapaah, E. A., & Carbone, L. D. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102151 · Cited by 2
“…use compared to the placebo at the lumbar spine (1.4% in the treatment group versus −1.6% in the placebo) and the trochanter (−0.4% in the treatment group versus −4% in the placebo) [163] These studies also showed that across trials, ALN consistently suppressed bone turnover markers (BTMs).”
InfluentialTraitement médicamenteux des ostéoporoses post-ménopausiques et cortisoniques
Roux, C. (2002) · Revue du Rhumatisme · doi:10.1016/s1169-8330(02)00426-x · Cited by 2
Ácido risedrónico frente a ácido zoledrónico
Henríquez, M. S. (2008) · Revista Española de Enfermedades Metabólicas Óseas · doi:10.1016/s1132-8460(08)72483-8 · Cited by 2
Pathogenese und Therapie der Steroid-induzierten Osteoporose
Braun, J., Buttgereit, F., Felsenberg, D., & Sieper, J. (2001) · Zeitschrift für Rheumatologie · doi:10.1007/s003930170082 · Cited by 2
Glukokortikoid-induzierte Osteoporose – Fokus Therapie (Teil 2)
Oelzner, P., Eidner, T., & Pfeil, A. (2022) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01128-7 · Cited by 2
Brance, M. L., Larroudé, M. S., Somma, L. F., Giacoia, E., Diehl, M., Galich, A. M., Stieben, L. A. R., Maher, M. C., Vega, M. D. L., Ringer, A., et al. (2023) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2022.10.002 · Cited by 2
Osteoporosis in Health and Disease: A Dermatologist's Perspective
Lamb, A. J., & Werth, V. P. (2006) · Dermatologic Clinics · doi:10.1016/j.det.2006.01.013 · Cited by 2
“It is possible that risedronate has fewer gastrointestinal side effects than alendronate, but this is not proven [39,51,52].”
BackgroundYavropoulou, M. P., ter Wee, M. M., Naciu, A. M., Paccou, J., Anastasilakis, A. D., Gialouri, C. G., Hauser, B., Sølling, A. S., D’Oronzo, S., Rolvien, T., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag147 · Cited by 1
NEW ASPECTS IN THE DIAGNOSIS AND TREATMENT OF GLUCOCORTICOID OSTEOPOROSIS
Baranova, I. A., & Toroptsova, N. V. (2013) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2013336-40 · Cited by 1
Skeletal Fragility, a Common Menopausal Burden: Risk Assessment, Diagnosis, and Management
Holick, M. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4_8 · Cited by 1
Garcés, F. M., Alvarez, R. M., Mollinedo, F. T., Orcasitas, A. C., & Maguregui, A. A. (2015) · Revista de la Sociedad Española del Dolor · doi:10.4321/s1134-80462015000200006 · Cited by 1
“Respecto al tratamiento el alendronato y el risedronato son eficaces en la prevención de la fractura osteoporótica y constituyen los fármacos de elección (7,8).”
BackgroundOsteoporosis in Rheumatologic Conditions and Inflammatory Disorders
Oleson, C. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_12 · Cited by 1
Basic and clinical aspects of glucocorticoid action in bone
Zhou, H., Cooper, M. S., & Seibel, M. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00039-7 · Cited by 1
Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Ruggiero, C., Caffarelli, C., Calsolaro, V., Tafaro, L., Riuzzi, F., Bubba, V., Napoli, N., Ferracci, M., Mecocci, P., Giusti, A., et al. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01163-4 · Cited by 1
Mechanismen des Knochenmasseverlustes bei rheumatoider Arthritis: Darstellung anhand einer Kasuistik
Oelzner, P., Buttgereit, F., Demary, W., Franck, H., Kern, P., & Hein, G. E. (2007) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-007-0157-5 · Cited by 1
Nonsteroid Immunosuppressive Agents and Bone
Epstein, S., & Inzerillo, A. M. (2004) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1385/bmm:2:2:091 · Cited by 1
Bisphosphonate Therapy for the Treatment of Postmenopausal Osteoporosis
Devogelaer, J., Boutsen, Y., & Manicourt, D. H. (2005) · Aging Health · doi:10.2217/1745509x.1.3.459 · Cited by 1
Self-citationCrandall, C. J. (2017) · Cited by 1
Tourinho, T. F. (2001) · Americanae (AECID Library) · Cited by 1
Stanford, P. E. (2012) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s3393
Moro-Álvarez, M. J., & Díaz Curiel, M. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70173-6
Prise en charge de l'ostéoporose cortisonique en 2005
Orcel, P. (2005) · Revue du Rhumatisme · doi:10.1016/j.rhum.2005.09.007
Polyarthrite rhumatoïde et bisphosphonates
Breuil, V., & Euller‐Ziegler, L. (2006) · Revue du Rhumatisme · doi:10.1016/j.rhum.2005.10.022
Prévention et traitement de l'ostéoporose (deuxième partie)
Cloutier, I. (2001) · Pharmactuel
Osteoporosis y Metabolismo Mineral
Díez Pérez, A., Manteca, L. A., Izquierdo Delgado, E., Andrés Calvo, M., Vega Tejedor, G., Mendo González, M., Jl, P. C., Ivorra Cortés, J., Ivorra, R., Jj, A. S., et al. (2010)
Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis
Roux, C., Dougados, M., & Cochin, H. (2000)
The Impact of Regulatory and Scientific Organizations’ Recommendations on Clinical Decision-Making
Παπαϊωάννου, Α., Agarwal, A., & Karampatos, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_21
Yassin, M. A., Khan, F. Y., Ani, A. A., & Othman, M. E. (2006) · Qatar medical journal · doi:10.5339/qmj.2006.2.22
Prophylaxe und Therapie der Glukokortikoid-induzierten Osteoporose
Oelzner, P., & Wolf, G. (2017) · Aktuelle Rheumatologie · doi:10.1055/s-0042-124182
“In anderen Studien wurde ein Erhalt der BMD unter dem Bisphosphonat bei gleichzeitiger BMD-Reduktion im Placebo-Arm gezeigt [41, 42].”
BackgroundThe Pathogenesis of Glucocorticoid-Induced Bone Loss
Devogelaer, J.-P., Boutsen, Y., & Manicourt, D. H. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-03437-1.50028-2
Self-citationEl hueso en el hipercortisolismo endógeno y exógeno
Martín, A. G., & Reyes‐García, R. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-503-5.00008-3
Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture
Hant, F. N., & Bolster, M. B. (2020) · Springer eBooks · doi:10.1007/978-3-030-33861-9_4
Einfluss der Pharmakotherapie auf die Kollagencrosslinkausscheidung bei rheumatoider Arthritis
Kummer, L. M. (2008) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Osteoporosis: A silent disease fraught with fragility fractures in geriatric population
Vashisht, A. (2021) · Annals of Geriatric Education and Medical Sciences · doi:10.18231/j.agems.2021.004
Estudio epidemiológico de la osteorporosis en la población española con artritis reumatoide
(n.d.) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
腎代替療法実施患者の感染モニタリングと新規の腎移植免疫抑制薬候補化合物に関する研究
草野, 淳. (2021) · Institutional Repositories DataBase (IRDB)
Metadata
- Authors
- Eastell, R., Devogelaer, J.-P., Peel, N. F. A., Chines, A. A., Bax, D. E., Sacco-Gibson, N., Nagant de Deuxchaisnes, C., & Russell, R. G. G.
- Affiliations
- University of Sheffield (GB)
- Procter & Gamble (United States) (US)
- Venue
- Osteoporosis International
- Published
- 2000-05-01
- Volume
- 11
- Issue
- 4
- Pages
- 331-337
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2018601087
- Cited by
- 134
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- risedronate, bone mineral density, bone loss prevention, rheumatoid arthritis, glucocorticoid-induced osteoporosis, postmenopausal women, bisphosphonates, prednisolone, lumbar spine, femoral neck, trochanter, treatment withdrawal
- MeSH terms
- Risedronic Acid, Administration, Oral, Aged, Arthritis, Rheumatoid, Calcium Channel Blockers, Double-Blind Method, Female, Glucocorticoids, Humans, Osteoporosis, Prednisolone, Etidronic Acid, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.